Gujarat Kidney FY26 Results: Standalone revenue up 14%, PAT rises 9%
- Standalone revenue grew 14% YoY to ₹4,010.02 lakh for FY26
- Net profit after tax rose 8.7% to ₹990.14 lakh
- Consolidated revenue more than doubled to ₹8,201.34 lakh due to acquisitions
- IPO raised ₹250.80 crore; ₹190.23 crore utilized by March 2026

*this image is generated using AI for illustrative purposes only.
Gujarat Kidney and Superspeciality reported a 14% increase in standalone revenue to ₹4,010.02 lakh for the fiscal year ended March 31, 2026. Standalone profit after tax rose 8.7% to ₹990.14 lakh from ₹910.90 lakh in the previous year.
The company consolidated its expansion through an Initial Public Offering (IPO) that raised ₹250.80 crore in December 2025. Consolidated revenue more than doubled to ₹8,201.34 lakh, driven by acquisitions of Harmony Medicare, Parekhs Hospital, and other entities during the year.
Financial Performance
Standalone profit before tax grew 3.7% to ₹1,254.70 lakh. Total expenses rose to ₹2,804.77 lakh from ₹2,318.43 lakh, reflecting higher professional fees and expected credit losses.
| Metric | FY26 (₹ Lakh) | FY25 (₹ Lakh) | Change |
|---|---|---|---|
| Revenue | 4,010.02 | 3,516.70 | +14.0% |
| Profit Before Tax | 1,254.70 | 1,209.67 | +3.7% |
| Profit After Tax | 990.14 | 910.90 | +8.7% |
Consolidated net profit attributable to owners of the company reached ₹1,549.69 lakh, up from ₹941.31 lakh in FY25. The group recorded total comprehensive income of ₹1,678.22 lakh.
IPO Utilization
The company utilized ₹190.23 crore of the ₹250.80 crore raised through the IPO as of March 31, 2026. Funds were deployed for acquiring Parekhs Hospital (₹77.00 crore), Ashwini Medical Centre (₹12.40 crore), and additional stake in Harmony Medicare (₹10.78 crore). ₹74.82 crore was used for inorganic growth and general corporate purposes.
What the Numbers Show
While standalone revenue grew steadily at 14%, the consolidated revenue surge to over ₹8,200 lakh indicates significant contribution from newly acquired entities. The acquisition of goodwill totaling ₹9,073.21 lakh on a consolidated basis suggests premium valuations paid for these hospital chains. Operating cash flow from standalone activities turned negative at -₹745.86 lakh, primarily due to a ₹607.78 lakh increase in trade receivables, signaling potential collection pressure amidst rapid expansion.
Historical Stock Returns for Gujarat Kidney and Super Speciality
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.91% | +12.58% | +34.71% | +55.35% | 0.0% | 0.0% |
How will the negative standalone operating cash flow and rising trade receivables impact the company's liquidity as it integrates newly acquired hospitals?
What is the expected timeline for the acquired entities like Parekhs Hospital and Harmony Medicare to achieve synergies that offset the high goodwill valuation?
Will the remaining ₹60.57 crore from the IPO proceeds be allocated for further inorganic expansion or debt reduction to strengthen the balance sheet?


































